# A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

> **NCT04438304** · PHASE2 · COMPLETED · sponsor: **Clarity Pharmaceuticals Ltd** · enrollment: 45 (actual)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 64Cu-SARTATE

## Key facts

- **NCT ID:** NCT04438304
- **Lead sponsor:** Clarity Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2024-11-26
- **Final completion:** 2024-11-26
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04438304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04438304, "A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04438304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*